BioPharmSignal logoBioPharmSignal

Biotech News

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics, Inc. (CARM)Carisma Therapeutics, Inc.2026-06-25 13:46 ESTCompany update

Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc.

Open original release

Related news

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Therapeutics Provides Corporate Updates

CARMCarisma Therapeutics, Inc.2026-06-25 13:46 EST

Carisma Announces Delisting from Nasdaq and SEC Deregistration

XOMAXOMA Corporation2026-07-14 13:00 EST

XOMA Royalty Announces Closing of Its Acquisition by Ligand

View all latest news

Carisma Therapeutics, Inc.

Carisma Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CARMZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

CARMZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

CARMBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CARMGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

CARMMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
0.01 USD
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States